Yi‐Long Wu

Top papers

• Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

  Tony Mok, Yi‐Long Wu, Sumitra Thongprasert, et al.·2009·New England Journal of Medicine
  ↗ 8,224OA
• The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer

  Peter Goldstraw, Kari Chansky, John Crowley, et al.·2016·Journal of Thoracic Oncology
  ↗ 4,592OA
• Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

  Caicun Zhou, Yi‐Long Wu, Gongyan Chen, et al.·2011·The Lancet Oncology
  ↗ 4,089
• Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer

  Alice T. Shaw, Dong‐Wan Kim, Kazuhiko Nakagawa, et al.·2013·New England Journal of Medicine
  ↗ 3,396OA
• Lung cancer: current therapies and new targeted treatments

  Fred R. Hirsch, Giorgio V. Scagliotti, James L. Mulshine, et al.·2016·The Lancet
  ↗ 3,334OA
• Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer

  Tony Mok, Yi‐Long Wu, Myung‐Ju Ahn, et al.·2016·New England Journal of Medicine
  ↗ 3,294OA
• Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

  Tony Mok, Yi‐Long Wu, Iveta Kudaba, et al.·2019·The Lancet
  ↗ 3,291OA
• First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer

  Benjamin Solomon, Tony Mok, Dong‐Wan Kim, et al.·2014·New England Journal of Medicine
  ↗ 3,196OA
• Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

  Yi‐Long Wu, Caicun Zhou, Chengping Hu, et al.·2014·The Lancet Oncology
  ↗ 1,969
• Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer

  Yi‐Long Wu, Masahiro Tsuboi, Jie He, et al.·2020·New England Journal of Medicine
  ↗ 1,713OA
• Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

  Masahiro Fukuoka, Yi‐Long Wu, Sumitra Thongprasert, et al.·2011·Journal of Clinical Oncology
  ↗ 1,603
• Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

  James Chih‐Hsin Yang, Yi‐Long Wu, Martin Schüler, et al.·2015·The Lancet Oncology
  ↗ 1,576